108 related articles for article (PubMed ID: 25887065)
1. Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers.
Bunn PA; Kim ES
Clin Lung Cancer; 2015 Jul; 16(4):245-51. PubMed ID: 25887065
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of lymphovascular invasion compared with that of visceral pleural invasion in patients with pN0 non-small-cell lung cancer and a tumor diameter of 2 cm or smaller.
Tao H; Hayashi T; Sano F; Takahagi A; Tanaka T; Matsuda E; Okabe K
J Surg Res; 2013 Nov; 185(1):250-4. PubMed ID: 23830361
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
Wozniak AJ; Gadgeel SM
Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival.
Hung JJ; Wang CY; Huang MH; Huang BS; Hsu WH; Wu YC
J Thorac Cardiovasc Surg; 2007 Sep; 134(3):638-43. PubMed ID: 17723811
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
8. Surgical-pathologic factors affect long-term outcomes in stage IB (pT2 N0 M0) non-small cell lung cancer: a heterogeneous disease.
Hsu CP; Hsia JY; Chang GC; Chuang CY; Shai SE; Yang SS; Lee MC; Kwan PC
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):426-33. PubMed ID: 19619791
[TBL] [Abstract][Full Text] [Related]
9. [Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].
Wen HW; Huang WP; Liu TY; Ma K; Tao X; Zhu LR; Liao QP
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):920-4. PubMed ID: 24495686
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size.
Ou SH; Zell JA; Ziogas A; Anton-Culver H
Chest; 2008 Mar; 133(3):662-9. PubMed ID: 17925418
[TBL] [Abstract][Full Text] [Related]
11. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
[TBL] [Abstract][Full Text] [Related]
12. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.
Dediu M; Ion O; Ion R; Alexandru A; Median D; Gal C; Horvat T; Motas C; Motas N
J BUON; 2012; 17(2):317-22. PubMed ID: 22740212
[TBL] [Abstract][Full Text] [Related]
14. Identification of a low risk subgroup of stage IB lung adenocarcinoma patients.
Mizuno T; Ishii G; Nagai K; Yoshida J; Nishimura M; Mochizuki T; Kawai O; Hasebe T; Ochiai A
Lung Cancer; 2008 Dec; 62(3):302-8. PubMed ID: 18486987
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
[TBL] [Abstract][Full Text] [Related]
16. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
[TBL] [Abstract][Full Text] [Related]
17. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer.
Ball D; Mitchell A; Giroux D; Rami-Porta R;
J Thorac Oncol; 2013 Mar; 8(3):315-21. PubMed ID: 23334092
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.
Russell K; Healy B; Pantarotto J; Laurie SA; MacRae R; Sabri E; Wheatley-Price P
Clin Lung Cancer; 2014 May; 15(3):237-43. PubMed ID: 24461300
[TBL] [Abstract][Full Text] [Related]
19. Role of adjuvant chemotherapy in NSCLC (stages I to III).
Coleman MH; Bueno R
Surg Oncol Clin N Am; 2011 Oct; 20(4):757-67. PubMed ID: 21986270
[TBL] [Abstract][Full Text] [Related]
20. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
